retatrutide ada 2025 results Provides Substantial Weight Loss in Patients With Obesity or Overweight Retatrutide Delivers Significant Hemoglobin A1C

You may begin to notice a decrease in appetite and food cravings within the first few weeks, followed by gradual weight loss and improved blood sugar control over time

The 12mg maintenance dose requires 240 units (2.40mL), which absolutely demands a split injection

The SURPASS-1 trial demonstrated significant improvements in glycemic control and substantial reductions in body weight with all three doses of tirzepatide (5 mg, 10 mg, or 15 mg) compared to placebo over a 40-week period

Clinical trial dosing protocol Phase 2 and Phase 3 trials used a titration approach, starting at lower doses and increasing gradually to minimize gastrointestinal side effects